 | • レポートコード：GIR-23F3732 • 出版社/出版日：GlobalInfoResearch / 2023年2月 • レポート形態：英文、PDF、95ページ • 納品方法：Eメール（2~3営業日） • 産業分類：医薬品 |
| Single User | ￥501,120 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥751,680 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,002,240 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 「Global Acute Myeloid Leukemia Drugs Market」レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。 グローバルインフォリサーチ社（香港）の最新の調査によると、世界の急性骨髄性白血病治療薬の市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。 急性骨髄性白血病治療薬市場はタイプ（種類）とアプリケーション（用途）によって区分されます。2017年～2028年において、量と金額の観点からタイプ別およびアプリケーション別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。 タイプ別セグメントは次を対象にします。 ・DCレジメン、AVDレジメン、VCDレジメン アプリケーション別セグメントは次のように区分されます。 ・病院、診療所、その他 世界の急性骨髄性白血病治療薬市場の主要なマーケットプレーヤーは以下のとおりです。 ・Ambit Biosciences Corporation、Celgene Corporation、Cephalon、Clavis Pharma、Eisai、Genzyme Corporation、Sunesis Pharmaceuticals 地域別セグメントは次の地域・国を対象にします。 ・北米市場（米国、カナダ、メキシコ） ・ヨーロッパ市場（ドイツ、フランス、イギリス、ロシア、イタリア） ・アジア太平洋市場（日本、中国、韓国、インド、東南アジア、オーストラリア） ・南米市場（ブラジル、アルゼンチン、コロンビア） ・中東・アフリカ市場（サウジアラビア、UAE、エジプト、南アフリカ） ***** 目次(一部) ***** ・市場概要 - 急性骨髄性白血病治療薬の概要 - タイプ別分析（2017年vs2021年vs2028年）：DCレジメン、AVDレジメン、VCDレジメン - アプリケーション別分析（2017年vs2021年vs2028年）：病院、診療所、その他 - 世界の急性骨髄性白血病治療薬市場規模・予測 - 世界の急性骨髄性白血病治療薬生産能力分析 - 市場の成長要因・阻害要因・動向 ・メーカー情報（企業概要、製品概要、販売量、価格、売上） - Ambit Biosciences Corporation、Celgene Corporation、Cephalon、Clavis Pharma、Eisai、Genzyme Corporation、Sunesis Pharmaceuticals ・メーカー別市場シェア・市場集中度 ・地域別市場分析2017年-2028年 ・タイプ別分析2017年-2028年：DCレジメン、AVDレジメン、VCDレジメン ・アプリケーション別分析2017年-2028年：病院、診療所、その他 ・急性骨髄性白血病治療薬の北米市場分析 - 急性骨髄性白血病治療薬の北米市場：タイプ別市場規模2017年-2028年 - 急性骨髄性白血病治療薬の北米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：アメリカ、カナダ、メキシコなど ・急性骨髄性白血病治療薬のヨーロッパ市場分析 - ：急性骨髄性白血病治療薬のヨーロッパ市場：タイプ別市場規模2017年-2028年 - ：急性骨髄性白血病治療薬のヨーロッパ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど ・急性骨髄性白血病治療薬のアジア太平洋市場分析 - 急性骨髄性白血病治療薬のアジア太平洋市場：タイプ別市場規模2017年-2028年 - 急性骨髄性白血病治療薬のアジア太平洋市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど ・急性骨髄性白血病治療薬の南米市場分析 - 急性骨髄性白血病治療薬の南米市場：タイプ別市場規模2017年-2028年 - 急性骨髄性白血病治療薬の南米市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：ブラジル、アルゼンチンなど ・急性骨髄性白血病治療薬の中東・アフリカ市場分析 - 急性骨髄性白血病治療薬の中東・アフリカ市場：タイプ別市場規模2017年-2028年 - 急性骨髄性白血病治療薬の中東・アフリカ市場：アプリケーション別市場規模2017年-2028年 - 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど ・原材料および産業チェーン ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Acute Myeloid Leukemia Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Acute Myeloid Leukemia Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Acute Myeloid Leukemia Drugs global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While DC regimen segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Acute Myeloid Leukemia Drugs include Ambit Biosciences Corporation, Celgene Corporation, Cephalon, Clavis Pharma, and Eisai, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Acute Myeloid Leukemia Drugs market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
DC regimen
AVD Regimen
VCD regimen
Market segment by Application can be divided into
Hospital
Clinic
Others
The key market players for global Acute Myeloid Leukemia Drugs market are listed below:
Ambit Biosciences Corporation
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Acute Myeloid Leukemia Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Acute Myeloid Leukemia Drugs, with price, sales, revenue and global market share of Acute Myeloid Leukemia Drugs from 2019 to 2022.
Chapter 3, the Acute Myeloid Leukemia Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Acute Myeloid Leukemia Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Acute Myeloid Leukemia Drugs market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Acute Myeloid Leukemia Drugs.
Chapter 13, 14, and 15, to describe Acute Myeloid Leukemia Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Acute Myeloid Leukemia Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Acute Myeloid Leukemia Drugs Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 DC regimen
1.2.3 AVD Regimen
1.2.4 VCD regimen
1.3 Market Analysis by Application
1.3.1 Overview: Global Acute Myeloid Leukemia Drugs Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Acute Myeloid Leukemia Drugs Market Size & Forecast
1.4.1 Global Acute Myeloid Leukemia Drugs Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Acute Myeloid Leukemia Drugs Sales in Volume (2017-2028)
1.4.3 Global Acute Myeloid Leukemia Drugs Price (2017-2028)
1.5 Global Acute Myeloid Leukemia Drugs Production Capacity Analysis
1.5.1 Global Acute Myeloid Leukemia Drugs Total Production Capacity (2017-2028)
1.5.2 Global Acute Myeloid Leukemia Drugs Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Acute Myeloid Leukemia Drugs Market Drivers
1.6.2 Acute Myeloid Leukemia Drugs Market Restraints
1.6.3 Acute Myeloid Leukemia Drugs Trends Analysis
2 Manufacturers Profiles
2.1 Ambit Biosciences Corporation
2.1.1 Ambit Biosciences Corporation Details
2.1.2 Ambit Biosciences Corporation Major Business
2.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product and Services
2.1.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Celgene Corporation
2.2.1 Celgene Corporation Details
2.2.2 Celgene Corporation Major Business
2.2.3 Celgene Corporation Acute Myeloid Leukemia Drugs Product and Services
2.2.4 Celgene Corporation Acute Myeloid Leukemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 Cephalon
2.3.1 Cephalon Details
2.3.2 Cephalon Major Business
2.3.3 Cephalon Acute Myeloid Leukemia Drugs Product and Services
2.3.4 Cephalon Acute Myeloid Leukemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Clavis Pharma
2.4.1 Clavis Pharma Details
2.4.2 Clavis Pharma Major Business
2.4.3 Clavis Pharma Acute Myeloid Leukemia Drugs Product and Services
2.4.4 Clavis Pharma Acute Myeloid Leukemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5 Eisai
2.5.1 Eisai Details
2.5.2 Eisai Major Business
2.5.3 Eisai Acute Myeloid Leukemia Drugs Product and Services
2.5.4 Eisai Acute Myeloid Leukemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6 Genzyme Corporation
2.6.1 Genzyme Corporation Details
2.6.2 Genzyme Corporation Major Business
2.6.3 Genzyme Corporation Acute Myeloid Leukemia Drugs Product and Services
2.6.4 Genzyme Corporation Acute Myeloid Leukemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7 Sunesis Pharmaceuticals
2.7.1 Sunesis Pharmaceuticals Details
2.7.2 Sunesis Pharmaceuticals Major Business
2.7.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product and Services
2.7.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Acute Myeloid Leukemia Drugs Breakdown Data by Manufacturer
3.1 Global Acute Myeloid Leukemia Drugs Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Acute Myeloid Leukemia Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Acute Myeloid Leukemia Drugs
3.4 Market Concentration Rate
3.4.1 Top 3 Acute Myeloid Leukemia Drugs Manufacturer Market Share in 2021
3.4.2 Top 6 Acute Myeloid Leukemia Drugs Manufacturer Market Share in 2021
3.5 Global Acute Myeloid Leukemia Drugs Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Acute Myeloid Leukemia Drugs Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Acute Myeloid Leukemia Drugs Market Size by Region
4.1.1 Global Acute Myeloid Leukemia Drugs Sales in Volume by Region (2017-2028)
4.1.2 Global Acute Myeloid Leukemia Drugs Revenue by Region (2017-2028)
4.2 North America Acute Myeloid Leukemia Drugs Revenue (2017-2028)
4.3 Europe Acute Myeloid Leukemia Drugs Revenue (2017-2028)
4.4 Asia-Pacific Acute Myeloid Leukemia Drugs Revenue (2017-2028)
4.5 South America Acute Myeloid Leukemia Drugs Revenue (2017-2028)
4.6 Middle East and Africa Acute Myeloid Leukemia Drugs Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Acute Myeloid Leukemia Drugs Sales in Volume by Type (2017-2028)
5.2 Global Acute Myeloid Leukemia Drugs Revenue by Type (2017-2028)
5.3 Global Acute Myeloid Leukemia Drugs Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Acute Myeloid Leukemia Drugs Sales in Volume by Application (2017-2028)
6.2 Global Acute Myeloid Leukemia Drugs Revenue by Application (2017-2028)
6.3 Global Acute Myeloid Leukemia Drugs Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Acute Myeloid Leukemia Drugs Sales by Type (2017-2028)
7.2 North America Acute Myeloid Leukemia Drugs Sales by Application (2017-2028)
7.3 North America Acute Myeloid Leukemia Drugs Market Size by Country
7.3.1 North America Acute Myeloid Leukemia Drugs Sales in Volume by Country (2017-2028)
7.3.2 North America Acute Myeloid Leukemia Drugs Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Acute Myeloid Leukemia Drugs Sales by Type (2017-2028)
8.2 Europe Acute Myeloid Leukemia Drugs Sales by Application (2017-2028)
8.3 Europe Acute Myeloid Leukemia Drugs Market Size by Country
8.3.1 Europe Acute Myeloid Leukemia Drugs Sales in Volume by Country (2017-2028)
8.3.2 Europe Acute Myeloid Leukemia Drugs Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Acute Myeloid Leukemia Drugs Sales by Type (2017-2028)
9.2 Asia-Pacific Acute Myeloid Leukemia Drugs Sales by Application (2017-2028)
9.3 Asia-Pacific Acute Myeloid Leukemia Drugs Market Size by Region
9.3.1 Asia-Pacific Acute Myeloid Leukemia Drugs Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Acute Myeloid Leukemia Drugs Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Acute Myeloid Leukemia Drugs Sales by Type (2017-2028)
10.2 South America Acute Myeloid Leukemia Drugs Sales by Application (2017-2028)
10.3 South America Acute Myeloid Leukemia Drugs Market Size by Country
10.3.1 South America Acute Myeloid Leukemia Drugs Sales in Volume by Country (2017-2028)
10.3.2 South America Acute Myeloid Leukemia Drugs Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Type (2017-2028)
11.2 Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Application (2017-2028)
11.3 Middle East & Africa Acute Myeloid Leukemia Drugs Market Size by Country
11.3.1 Middle East & Africa Acute Myeloid Leukemia Drugs Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Acute Myeloid Leukemia Drugs Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Acute Myeloid Leukemia Drugs and Key Manufacturers
12.2 Manufacturing Costs Percentage of Acute Myeloid Leukemia Drugs
12.3 Acute Myeloid Leukemia Drugs Production Process
12.4 Acute Myeloid Leukemia Drugs Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Acute Myeloid Leukemia Drugs Typical Distributors
13.3 Acute Myeloid Leukemia Drugs Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer
Table 1. Global Acute Myeloid Leukemia Drugs Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Acute Myeloid Leukemia Drugs Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. Ambit Biosciences Corporation Basic Information, Manufacturing Base and Competitors
Table 4. Ambit Biosciences Corporation Major Business
Table 5. Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Product and Services
Table 6. Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Celgene Corporation Basic Information, Manufacturing Base and Competitors
Table 8. Celgene Corporation Major Business
Table 9. Celgene Corporation Acute Myeloid Leukemia Drugs Product and Services
Table 10. Celgene Corporation Acute Myeloid Leukemia Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Cephalon Basic Information, Manufacturing Base and Competitors
Table 12. Cephalon Major Business
Table 13. Cephalon Acute Myeloid Leukemia Drugs Product and Services
Table 14. Cephalon Acute Myeloid Leukemia Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Clavis Pharma Basic Information, Manufacturing Base and Competitors
Table 16. Clavis Pharma Major Business
Table 17. Clavis Pharma Acute Myeloid Leukemia Drugs Product and Services
Table 18. Clavis Pharma Acute Myeloid Leukemia Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Eisai Basic Information, Manufacturing Base and Competitors
Table 20. Eisai Major Business
Table 21. Eisai Acute Myeloid Leukemia Drugs Product and Services
Table 22. Eisai Acute Myeloid Leukemia Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 23. Genzyme Corporation Basic Information, Manufacturing Base and Competitors
Table 24. Genzyme Corporation Major Business
Table 25. Genzyme Corporation Acute Myeloid Leukemia Drugs Product and Services
Table 26. Genzyme Corporation Acute Myeloid Leukemia Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 27. Sunesis Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 28. Sunesis Pharmaceuticals Major Business
Table 29. Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Product and Services
Table 30. Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 31. Global Acute Myeloid Leukemia Drugs Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 32. Global Acute Myeloid Leukemia Drugs Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 33. Market Position of Manufacturers in Acute Myeloid Leukemia Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 34. Global Acute Myeloid Leukemia Drugs Production Capacity by Company, (K Units): 2020 VS 2021
Table 35. Head Office and Acute Myeloid Leukemia Drugs Production Site of Key Manufacturer
Table 36. Acute Myeloid Leukemia Drugs New Entrant and Capacity Expansion Plans
Table 37. Acute Myeloid Leukemia Drugs Mergers & Acquisitions in the Past Five Years
Table 38. Global Acute Myeloid Leukemia Drugs Sales by Region (2017-2022) & (K Units)
Table 39. Global Acute Myeloid Leukemia Drugs Sales by Region (2023-2028) & (K Units)
Table 40. Global Acute Myeloid Leukemia Drugs Revenue by Region (2017-2022) & (USD Million)
Table 41. Global Acute Myeloid Leukemia Drugs Revenue by Region (2023-2028) & (USD Million)
Table 42. Global Acute Myeloid Leukemia Drugs Sales by Type (2017-2022) & (K Units)
Table 43. Global Acute Myeloid Leukemia Drugs Sales by Type (2023-2028) & (K Units)
Table 44. Global Acute Myeloid Leukemia Drugs Revenue by Type (2017-2022) & (USD Million)
Table 45. Global Acute Myeloid Leukemia Drugs Revenue by Type (2023-2028) & (USD Million)
Table 46. Global Acute Myeloid Leukemia Drugs Price by Type (2017-2022) & (USD/Unit)
Table 47. Global Acute Myeloid Leukemia Drugs Price by Type (2023-2028) & (USD/Unit)
Table 48. Global Acute Myeloid Leukemia Drugs Sales by Application (2017-2022) & (K Units)
Table 49. Global Acute Myeloid Leukemia Drugs Sales by Application (2023-2028) & (K Units)
Table 50. Global Acute Myeloid Leukemia Drugs Revenue by Application (2017-2022) & (USD Million)
Table 51. Global Acute Myeloid Leukemia Drugs Revenue by Application (2023-2028) & (USD Million)
Table 52. Global Acute Myeloid Leukemia Drugs Price by Application (2017-2022) & (USD/Unit)
Table 53. Global Acute Myeloid Leukemia Drugs Price by Application (2023-2028) & (USD/Unit)
Table 54. North America Acute Myeloid Leukemia Drugs Sales by Country (2017-2022) & (K Units)
Table 55. North America Acute Myeloid Leukemia Drugs Sales by Country (2023-2028) & (K Units)
Table 56. North America Acute Myeloid Leukemia Drugs Revenue by Country (2017-2022) & (USD Million)
Table 57. North America Acute Myeloid Leukemia Drugs Revenue by Country (2023-2028) & (USD Million)
Table 58. North America Acute Myeloid Leukemia Drugs Sales by Type (2017-2022) & (K Units)
Table 59. North America Acute Myeloid Leukemia Drugs Sales by Type (2023-2028) & (K Units)
Table 60. North America Acute Myeloid Leukemia Drugs Sales by Application (2017-2022) & (K Units)
Table 61. North America Acute Myeloid Leukemia Drugs Sales by Application (2023-2028) & (K Units)
Table 62. Europe Acute Myeloid Leukemia Drugs Sales by Country (2017-2022) & (K Units)
Table 63. Europe Acute Myeloid Leukemia Drugs Sales by Country (2023-2028) & (K Units)
Table 64. Europe Acute Myeloid Leukemia Drugs Revenue by Country (2017-2022) & (USD Million)
Table 65. Europe Acute Myeloid Leukemia Drugs Revenue by Country (2023-2028) & (USD Million)
Table 66. Europe Acute Myeloid Leukemia Drugs Sales by Type (2017-2022) & (K Units)
Table 67. Europe Acute Myeloid Leukemia Drugs Sales by Type (2023-2028) & (K Units)
Table 68. Europe Acute Myeloid Leukemia Drugs Sales by Application (2017-2022) & (K Units)
Table 69. Europe Acute Myeloid Leukemia Drugs Sales by Application (2023-2028) & (K Units)
Table 70. Asia-Pacific Acute Myeloid Leukemia Drugs Sales by Region (2017-2022) & (K Units)
Table 71. Asia-Pacific Acute Myeloid Leukemia Drugs Sales by Region (2023-2028) & (K Units)
Table 72. Asia-Pacific Acute Myeloid Leukemia Drugs Revenue by Region (2017-2022) & (USD Million)
Table 73. Asia-Pacific Acute Myeloid Leukemia Drugs Revenue by Region (2023-2028) & (USD Million)
Table 74. Asia-Pacific Acute Myeloid Leukemia Drugs Sales by Type (2017-2022) & (K Units)
Table 75. Asia-Pacific Acute Myeloid Leukemia Drugs Sales by Type (2023-2028) & (K Units)
Table 76. Asia-Pacific Acute Myeloid Leukemia Drugs Sales by Application (2017-2022) & (K Units)
Table 77. Asia-Pacific Acute Myeloid Leukemia Drugs Sales by Application (2023-2028) & (K Units)
Table 78. South America Acute Myeloid Leukemia Drugs Sales by Country (2017-2022) & (K Units)
Table 79. South America Acute Myeloid Leukemia Drugs Sales by Country (2023-2028) & (K Units)
Table 80. South America Acute Myeloid Leukemia Drugs Revenue by Country (2017-2022) & (USD Million)
Table 81. South America Acute Myeloid Leukemia Drugs Revenue by Country (2023-2028) & (USD Million)
Table 82. South America Acute Myeloid Leukemia Drugs Sales by Type (2017-2022) & (K Units)
Table 83. South America Acute Myeloid Leukemia Drugs Sales by Type (2023-2028) & (K Units)
Table 84. South America Acute Myeloid Leukemia Drugs Sales by Application (2017-2022) & (K Units)
Table 85. South America Acute Myeloid Leukemia Drugs Sales by Application (2023-2028) & (K Units)
Table 86. Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Region (2017-2022) & (K Units)
Table 87. Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Region (2023-2028) & (K Units)
Table 88. Middle East & Africa Acute Myeloid Leukemia Drugs Revenue by Region (2017-2022) & (USD Million)
Table 89. Middle East & Africa Acute Myeloid Leukemia Drugs Revenue by Region (2023-2028) & (USD Million)
Table 90. Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Type (2017-2022) & (K Units)
Table 91. Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Type (2023-2028) & (K Units)
Table 92. Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Application (2017-2022) & (K Units)
Table 93. Middle East & Africa Acute Myeloid Leukemia Drugs Sales by Application (2023-2028) & (K Units)
Table 94. Acute Myeloid Leukemia Drugs Raw Material
Table 95. Key Manufacturers of Acute Myeloid Leukemia Drugs Raw Materials
Table 96. Direct Channel Pros & Cons
Table 97. Indirect Channel Pros & Cons
Table 98. Acute Myeloid Leukemia Drugs Typical Distributors
Table 99. Acute Myeloid Leukemia Drugs Typical Customers
List of Figures
Figure 1. Acute Myeloid Leukemia Drugs Picture
Figure 2. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type in 2021
Figure 3. DC regimen
Figure 4. AVD Regimen
Figure 5. VCD regimen
Figure 6. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application in 2021
Figure 7. Hospital
Figure 8. Clinic
Figure 9. Others
Figure 10. Global Acute Myeloid Leukemia Drugs Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 11. Global Acute Myeloid Leukemia Drugs Revenue and Forecast (2017-2028) & (USD Million)
Figure 12. Global Acute Myeloid Leukemia Drugs Sales (2017-2028) & (K Units)
Figure 13. Global Acute Myeloid Leukemia Drugs Price (2017-2028) & (USD/Unit)
Figure 14. Global Acute Myeloid Leukemia Drugs Production Capacity (2017-2028) & (K Units)
Figure 15. Global Acute Myeloid Leukemia Drugs Production Capacity by Geographic Region: 2022 VS 2028
Figure 16. Acute Myeloid Leukemia Drugs Market Drivers
Figure 17. Acute Myeloid Leukemia Drugs Market Restraints
Figure 18. Acute Myeloid Leukemia Drugs Market Trends
Figure 19. Global Acute Myeloid Leukemia Drugs Sales Market Share by Manufacturer in 2021
Figure 20. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Manufacturer in 2021
Figure 21. Acute Myeloid Leukemia Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 22. Top 3 Acute Myeloid Leukemia Drugs Manufacturer (Revenue) Market Share in 2021
Figure 23. Top 6 Acute Myeloid Leukemia Drugs Manufacturer (Revenue) Market Share in 2021
Figure 24. Global Acute Myeloid Leukemia Drugs Sales Market Share by Region (2017-2028)
Figure 25. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Region (2017-2028)
Figure 26. North America Acute Myeloid Leukemia Drugs Revenue (2017-2028) & (USD Million)
Figure 27. Europe Acute Myeloid Leukemia Drugs Revenue (2017-2028) & (USD Million)
Figure 28. Asia-Pacific Acute Myeloid Leukemia Drugs Revenue (2017-2028) & (USD Million)
Figure 29. South America Acute Myeloid Leukemia Drugs Revenue (2017-2028) & (USD Million)
Figure 30. Middle East & Africa Acute Myeloid Leukemia Drugs Revenue (2017-2028) & (USD Million)
Figure 31. Global Acute Myeloid Leukemia Drugs Sales Market Share by Type (2017-2028)
Figure 32. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Type (2017-2028)
Figure 33. Global Acute Myeloid Leukemia Drugs Price by Type (2017-2028) & (USD/Unit)
Figure 34. Global Acute Myeloid Leukemia Drugs Sales Market Share by Application (2017-2028)
Figure 35. Global Acute Myeloid Leukemia Drugs Revenue Market Share by Application (2017-2028)
Figure 36. Global Acute Myeloid Leukemia Drugs Price by Application (2017-2028) & (USD/Unit)
Figure 37. North America Acute Myeloid Leukemia Drugs Sales Market Share by Type (2017-2028)
Figure 38. North America Acute Myeloid Leukemia Drugs Sales Market Share by Application (2017-2028)
Figure 39. North America Acute Myeloid Leukemia Drugs Sales Market Share by Country (2017-2028)
Figure 40. North America Acute Myeloid Leukemia Drugs Revenue Market Share by Country (2017-2028)
Figure 41. United States Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Canada Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 43. Mexico Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 44. Europe Acute Myeloid Leukemia Drugs Sales Market Share by Type (2017-2028)
Figure 45. Europe Acute Myeloid Leukemia Drugs Sales Market Share by Application (2017-2028)
Figure 46. Europe Acute Myeloid Leukemia Drugs Sales Market Share by Country (2017-2028)
Figure 47. Europe Acute Myeloid Leukemia Drugs Revenue Market Share by Country (2017-2028)
Figure 48. Germany Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. France Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. United Kingdom Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Russia Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 52. Italy Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 53. Asia-Pacific Acute Myeloid Leukemia Drugs Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Acute Myeloid Leukemia Drugs Sales Market Share by Application (2017-2028)
Figure 55. Asia-Pacific Acute Myeloid Leukemia Drugs Sales Market Share by Region (2017-2028)
Figure 56. Asia-Pacific Acute Myeloid Leukemia Drugs Revenue Market Share by Region (2017-2028)
Figure 57. China Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Japan Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Korea Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. India Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. Southeast Asia Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 62. Australia Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. South America Acute Myeloid Leukemia Drugs Sales Market Share by Type (2017-2028)
Figure 64. South America Acute Myeloid Leukemia Drugs Sales Market Share by Application (2017-2028)
Figure 65. South America Acute Myeloid Leukemia Drugs Sales Market Share by Country (2017-2028)
Figure 66. South America Acute Myeloid Leukemia Drugs Revenue Market Share by Country (2017-2028)
Figure 67. Brazil Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 68. Argentina Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 69. Middle East & Africa Acute Myeloid Leukemia Drugs Sales Market Share by Type (2017-2028)
Figure 70. Middle East & Africa Acute Myeloid Leukemia Drugs Sales Market Share by Application (2017-2028)
Figure 71. Middle East & Africa Acute Myeloid Leukemia Drugs Sales Market Share by Region (2017-2028)
Figure 72. Middle East & Africa Acute Myeloid Leukemia Drugs Revenue Market Share by Region (2017-2028)
Figure 73. Turkey Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Egypt Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Saudi Arabia Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South Africa Acute Myeloid Leukemia Drugs Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 77. Manufacturing Cost Structure Analysis of Acute Myeloid Leukemia Drugs in 2021
Figure 78. Manufacturing Process Analysis of Acute Myeloid Leukemia Drugs
Figure 79. Acute Myeloid Leukemia Drugs Industrial Chain
Figure 80. Sales Channel: Direct Channel vs Indirect Channel
Figure 81. Methodology
Figure 82. Research Process and Data Source
• 日本語訳：急性骨髄性白血病治療薬のグローバル市場2022年
• レポートコード：GIR-23F3732 ▷ お問い合わせ（見積依頼・ご注文・質問）